These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

321 related items for PubMed ID: 7037174

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Phase I clinical evaluation of 9,10-anthracenedicarboxyaldehyde[bis(4,5-dihydro-1H-imidazol-2-yl)hydrazone]dihydrochloride (bisantrene).
    Yap BS, Yap HY, Blumenschein GR, Bedikian AY, Pocelinko R, Bodey GP.
    Cancer Treat Rep; 1982 Jul; 66(7):1517-20. PubMed ID: 7093967
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Activity of a novel anthracenyl bishydrazone, 9,10-anthracenedicarboxyaldehyde Bis[(4,5-dihydro-1H-imidazol-2-yl)hydrazone] dihydrochloride, against experimental tumors in mice.
    Citarella RV, Wallace RE, Murdock KC, Angier RB, Durr FE, Forbes M.
    Cancer Res; 1982 Feb; 42(2):440-4. PubMed ID: 7055799
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Disposition of bisantrene in humans and rabbits: evidence for intravascular deposition of drug as a cause of phlebitis.
    Powis G, Kovach JS.
    Cancer Res; 1983 Feb; 43(2):925-9. PubMed ID: 6848203
    [Abstract] [Full Text] [Related]

  • 7. Phase I clinical investigation of 1,4-dihydroxy-5,8-bis (( (2-[(2-hydroxyethyl)amino]ethyl) amino))-9,10-anthracenedione dihydrochloride (NSC 301739), a new anthracenedione.
    Von Hoff DD, Pollard E, Kuhn J, Murray E, Coltman CA.
    Cancer Res; 1980 May; 40(5):1516-8. PubMed ID: 7370989
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas.
    Colón-Otero G, Marschke R, Camoriano JK, Sorensen JM, Sloan JA, Richardson RL.
    Cancer J Sci Am; 1997 May; 3(5):297-302. PubMed ID: 9327154
    [Abstract] [Full Text] [Related]

  • 10. Phase I and pharmacokinetic study of 10-propargyl-10-deazaaminopterin, a new antifolate.
    Krug LM, Ng KK, Kris MG, Miller VA, Tong W, Heelan RT, Leon L, Leung D, Kelly J, Grant SC, Sirotnak FM.
    Clin Cancer Res; 2000 Sep; 6(9):3493-8. PubMed ID: 10999734
    [Abstract] [Full Text] [Related]

  • 11. Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.
    Murren J, Modiano M, Clairmont C, Lambert P, Savaraj N, Doyle T, Sznol M.
    Clin Cancer Res; 2003 Sep 15; 9(11):4092-100. PubMed ID: 14519631
    [Abstract] [Full Text] [Related]

  • 12. Phase I trial of methotrexate-albumin in a weekly intravenous bolus regimen in cancer patients. Phase I Study Group of the Association for Medical Oncology of the German Cancer Society.
    Hartung G, Stehle G, Sinn H, Wunder A, Schrenk HH, Heeger S, Kränzle M, Edler L, Frei E, Fiebig HH, Heene DL, Maier-Borst W, Queisser W.
    Clin Cancer Res; 1999 Apr 15; 5(4):753-9. PubMed ID: 10213209
    [Abstract] [Full Text] [Related]

  • 13. Phase 1 clinical investigation of 4'-(9-acridinylamino)methanesulfon-m-anisidide (NSC 249992), a new acridine derivative.
    Legha SS, Gutterman JU, Hall SW, Benjamin RS, Burgess MA, Valdivieso M, Bodey GP.
    Cancer Res; 1978 Nov 15; 38(11 Pt 1):3712-6. PubMed ID: 279397
    [Abstract] [Full Text] [Related]

  • 14. Paclitaxel and simultaneous radiation in the treatment of stage IIIA/B non-small cell lung cancer.
    Wolf M, Faoro C, Goerg C, Pfab R, Havemann K, Kettner H.
    Semin Oncol; 1996 Dec 15; 23(6 Suppl 16):108-12. PubMed ID: 9007135
    [Abstract] [Full Text] [Related]

  • 15. Molecular pharmacology of the anthracycline drug 9,10-anthracenedicarboxaldehyde bis[(4,5-dihydro-1 H-imidazol-2-yl)hydrazone] dihydrochloride (Cl 216,942).
    Bowden GT, Garcia D, Peng YM, Alberts DS.
    Cancer Res; 1982 Jul 15; 42(7):2660-5. PubMed ID: 7083158
    [Abstract] [Full Text] [Related]

  • 16. Light, fluorescent, and electron microscopic analysis of cultured breast tumor cells (T-47D) treated with 9,10-anthracenedicarboxaldehyde bis[(4,5-dihydro-1H-imidazol-2-yl)hydrazone] dihydrochloride.
    Tseng MT, Safa AR.
    Cancer Res; 1983 Dec 15; 43(12 Pt 1):5910-4. PubMed ID: 6640539
    [Abstract] [Full Text] [Related]

  • 17. Phase I clinical and pharmacokinetic study of plitidepsin as a 1-hour weekly intravenous infusion in patients with advanced solid tumors.
    Izquierdo MA, Bowman A, García M, Jodrell D, Martinez M, Pardo B, Gómez J, López-Martin JA, Jimeno J, Germá JR, Smyth JF.
    Clin Cancer Res; 2008 May 15; 14(10):3105-12. PubMed ID: 18483378
    [Abstract] [Full Text] [Related]

  • 18. Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors.
    Supko JG, Eder JP, Ryan DP, Seiden MV, Lynch TJ, Amrein PC, Kufe DW, Clark JW.
    Clin Cancer Res; 2003 Nov 01; 9(14):5178-86. PubMed ID: 14613997
    [Abstract] [Full Text] [Related]

  • 19. A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia.
    Gimsing P, Hansen M, Knudsen LM, Knoblauch P, Christensen IJ, Ooi CE, Buhl-Jensen P.
    Eur J Haematol; 2008 Sep 01; 81(3):170-6. PubMed ID: 18510700
    [Abstract] [Full Text] [Related]

  • 20. Phase II evaluation of bisantrene in patients with advanced non-small cell lung carcinoma.
    Feld R, Evans WK, Shepherd FA, Deboer G, Ottema B.
    Cancer Treat Rep; 1985 Feb 01; 69(2):209-10. PubMed ID: 3971392
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.